Skeletal complications of malignancy

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1588-1594

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; LACTATE DEHYDROGENASE;

BACKACHE; BONE METASTASIS; BREAST CARCINOMA; CONFERENCE PAPER; DISEASE COURSE; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; NERVE COMPRESSION; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; SPINAL CORD COMPRESSION;

EID: 0030749321     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g     Document Type: Conference Paper

References (30)

1. Rubens RD, Coleman RE. Bone metastases. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Clinical oncology. New York: Churchill Livingstone, 1995:643-65.
2. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992; 28:690-2.
3. Koenders PG, Beex LVAM, Langens R, Kloppenborg PWC, Smals AGH, Benraad J, for the Breast Cancer Study Group. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. Breast Cancer Res Treat 1991;18:27-32.
4. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
5. Fan K, Peng C. Predicting the probability of bone metastasis through histological grading of prostate carcinoma: a retrospective correlative analysis of 81 autopsy cases with antemortem transurethral resection specimens. J Urol 1983; 57:715-20.
6. Batson OV. The role of the vertebral veins in the metastatic process. Ann Intern Med 1942;16:38.
7. Urwin GH, Percival RC, Harris S, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985;57:721.
8. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996;22:289-331.
9. Coleman RE, Vinholes J, Abbey ME, Purohit OP. Double blind randomised trial of pamidronate (Aredia) for the palliative treatment of metastatic bone disease. Proc ASCO 1996;15:528.
10. Coleman RE, Smith P, Rubens RD. Clinical course and prognostic factors following recurrence from breast cancer. Br J Cancer, in press.
11. Robson M, Dawson N. How is androgen dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996;10:727-47.
12. Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer: important implications for future trials. Results of a Co-operative Intergroup Study (INT 0036). Semin Oncol 1994;21:613-9.
13. Kyle RA, Blade J. Multiple myeloma and related disorders. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Clinical oncology. New York: Churchill Livingstone, 1995: 2053-73.
14. Bataille R, Boccadoro M, Klein B, et al. C-reactive protein and β2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80:733.
15. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 1996;335:1785-91.
16. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
17. McCloskey EV, O'Rourke N, Maclennan I, Greaves M, Preston FE, Kanis JA. Natural history of skeletal disease in multiple myelomatosis and treatment with clodronate. Bone Miner 1992;28:(Suppl 1):S27.
18. Morton AR, Lipton A. Hypercalcaemia. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Clinical oncology. New York: Churchill Livingstone, 1995:527-42.
19. Higinbotham NL, Marcove RC. The management of pathological fractures. J Trauma 1965;5:792.
20. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseus metastasis treated with combination chemotherapy. Cancer 1986;58:2589-93.
21. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
22. Body J-J, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996,22:265-87.
23. Rodichok LD, Ruckdeschel JC, Harper GR, et al. Early detection of spinal epidural metastases: the role of myelography. Ann Neurol 1986;20:696.
24. Kamholtz R, Sze G. Current imaging in spinal metastatic disease. Semin Oncol 1991;18:158-69.
25. Siegal T, Siegal T. Vertebral body resection for epidural compression by malignant tumours; results of forty-seven consecutive operative procedures. J Bone Joint Surg Am 1985;67:375-82.
26. Vinholes JJ, Purohit OP, Abbey ME, Eastell R. Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Annals Oncol, in press.
27. Vinholes JJ, Guo C-Y, Purohit OP, Eastell R, Coleman RE. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996;73:1089-95.
28. DeWald RL, Bridwell KH, Prodromas C, Rodts MF. Reconstructive spinal surgery as palliation for metastatic malignancies. Spine 1985;10:21-6.
29. Richards MA, Brayser S, Gregory WM, Rubens RD. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993;67:856-60.
30. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast. Bone 1991; 12 (Suppl 1):37-42.